Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


FGFR inhibitor erdafitinib for urothelial cancer is filed in Japan – Janssen Pharmaceutical

Written by | 1 Dec 2023

Janssen Pharmaceutical has filed a new drug application in Japan for its oral fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor erdafitinib for the treatment of certain patients… read more.

Keytruda (pembrolizumab) met a primary endpoint of disease-free survival in certain patients with muscle-invasive urothelial carcinoma after surgery – Merck Inc

Written by | 16 Oct 2023

Merck Inc., known as MSD outside of the United States and Canada, announced that the Phase III AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda, Merck’s anti-PD-1 therapy, met one… read more.

Padcev and Keytruda significantly improve overall survival and progression-free survival in previously untreated advanced bladder cancer in pivotal phase III EV-302 trial – Seagen + Astellas

Written by | 5 Oct 2023

Seagen Inc. and Astellas Pharma Inc. announced positive topline results from the Phase III EV-302 clinical trial (also known as KEYNOTE-A39) for Padcev (enfortumab vedotin-ejfv) in combination with… read more.

MAA is submitted to the European Medicines Agency seeking approval of erdafitinib for the treatment of patients with locally advanced or metastatic urothelial cancer with susceptible FGFR alterations – Janssen Pharmaceutical

Written by | 17 Sep 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of erdafitinib for… read more.

First-line Opdivo plus chemotherapy provides survival benefit in metastatic urothelial carcinoma (bladder cancer) – BMS

Written by | 24 Jul 2023

Frontline treatment with the combination of nivolumab (Opdivo) and cisplatin-based chemotherapy, followed by nivolumab monotherapy, led to a statistically significant improvement in progression-free survival (PFS) and overall survival… read more.

Alternative bladder cancer treatment emerges amid worldwide shortage of standard of care BCG

Written by | 3 Mar 2023

An on-going, worldwide shortage of bacillus Calmette-Guérin (BCG) means that many patients with a common and serious type of bladder cancer have limited access to this effective standard… read more.

Immunotherapy after surgery provides significant, durable benefit for high-risk bladder patients

Written by | 17 Feb 2023

Immunotherapy after surgery increased bladder cancer patients’ chance of staying cancer-free compared to patients who received a placebo, according to clinical trial results shared in a late-breaking oral… read more.

Novel treatment effective for bladder cancer, study in mice shows

Written by | 17 Oct 2022

An epigenetics drug currently being used for the treatment of blood cancers and rare sarcomas can stop the growth of bladder cancer by activating the immune system, reports… read more.

Urology Week 2022 – Bladder Cancer Overview

Written by | 19 Sep 2022

Every year the European Association of Urology (EAU) hosts Urology Week, an international campaign for increasing awareness of urological conditions and treatment. This year, Urology Week (26-30 September… read more.

Why bladder cancer matters

Written by | 19 Sep 2022

Bladder cancer is the 5th most common tumour in men and the 7-8th most common tumour women, according to Professor Arnulf Stenzl, Head of the Department of Urology in the… read more.

Re-TUR: depends on surgeon skill or tumour biology?

Written by | 19 Sep 2022

Current guidelines recommend a repeat TUR (re-TUR) for T1 bladder tumours but this carries risks and could be avoided if a good, complete TUR is done in the… read more.

Cystectomy vs trimodality bladder preserving treatment for muscle invasive bladder cancer (MIBC)

Written by | 19 Sep 2022

According to the updated EAU guidelines long-term survival with trimodality bladder preserving treatment (TMT) could be as good as with radical cystectomy (RC), in selected patients. During the… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.